Non-Alcoholic Fatty Liver Disease (NAFLD) Pipeline Assessment (2023 Updates) | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Competitive Landscape, and Treatment Outlook | Key Companies - AngioLab, Galect

As per DelveInsight's assessment, globally, about 110+ key pharma and biotech companies are working on 160+ pipeline drugs in the Non-Alcoholic Fatty Liver Disease (NAFLD) therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

"Non-Alcoholic Fatty Liver Disease (NAFLD) Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Non-Alcoholic Fatty Liver Disease Therapeutics Market.

The report provides a detailed description of the drug, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Non-Alcoholic Fatty Liver Disease (NAFLD) Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing therapies in the Non-Alcoholic Fatty Liver Disease Market.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Non-Alcoholic Fatty Liver Disease treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Non-Alcoholic Fatty Liver Disease market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Learn More about the Clinical and Commercial Development Activities in the Non-Alcoholic Fatty Liver Disease Therapeutics Domain:
https://www.delveinsight.com/report-store/non-alcoholic-fatty-liver-disease-nafld-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

The Report Covers the Emerging Pipeline Products Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration
Non-Alcoholic Fatty Liver Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type
Products have been categorized under various Molecule types such as
• Oligonucleotide
• Peptide
• Small molecule

Request for Sample PDF to Understand More About the Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/sample-request/non-alcoholic-fatty-liver-disease-nafld-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Non-Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Analysis
There are approx. 120+ key companies which are developing the therapies for Non-Alcoholic Fatty Liver Disease. Currently, Inventiva Pharma is leading the therapeutics market with its Non-Alcoholic Fatty Liver Disease drug candidates in the most advanced stage of clinical development.

The Leading Companies in the Non-Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Market Include:
Afimmune, Alnylam Pharmaceuticals, Inc., AngioLab, AstraZeneca, BeiGene, Can Fite Biopharma, Chemomab Therapeutics, Cirius Therapeutics, CytoDyn, Inc., Dr. Falk Pharma GmbH, Eli Lilly and Company, Galectin Therapeutics, Galmed Pharmaceuticals Hanmi Pharmaceutical, Hepagene Therapeutics, HighTide Biopharma, HK inno.N, Inventiva Pharma, Ionis Pharmaceuticals, Kowa Pharmaceutical, Lipocine, Inc., MediciNova, Metacrine, Inc., Mitsubishi Tanabe Pharma, NorthSea Therapeutics, Novartis Pharmaceuticals, Novo Nordisk, NuSirt Biopharma, Oramed Pharmacetuicals, Pfizer, Poxel SA, Rivus Pharmaceuticals, Sagimet Biosciences, Sinew Pharma, Terns Pharmaceuticals, Viking Therapeutics, and many others.

Non-Alcoholic Fatty Liver Disease Emerging and Marketed Drugs Covered in the Report Include:
• ALS-L1023: AngioLab
• Belapectin: Galectin Therapeutics
• Lanifibranor: Inventiva Pharma
• MGL-3196 (Resmetirom): Madrigal Pharmaceuticals
• MN-001: MediciNova
• Pegozafermin: 89bio, Inc.
• Tirzepatide: Eli Lilly and Company
• TVB-2640: Sagimet Biosciences
• ZED 1227: Dr. Falk Pharma GmbH
And Many More

Get an in-depth Assessment of the Emerging Therapies and Key Companies:
https://www.delveinsight.com/sample-request/non-alcoholic-fatty-liver-disease-nafld-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content
1. Report Introduction
2. Executive Summary
3. Non-Alcoholic Fatty Liver Disease Current Treatment Patterns
4. Non-Alcoholic Fatty Liver Disease - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Non-Alcoholic Fatty Liver Disease Late-Stage Products (Phase-III)
7. Non-Alcoholic Fatty Liver Disease Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Non-Alcoholic Fatty Liver Disease Discontinued Products
13. Non-Alcoholic Fatty Liver Disease Product Profiles
14. Non-Alcoholic Fatty Liver Disease Key Companies
15. Non-Alcoholic Fatty Liver Disease Key Products
16. Dormant and Discontinued Products
17. Non-Alcoholic Fatty Liver Disease Unmet Needs
18. Non-Alcoholic Fatty Liver Disease Future Perspectives
19. Non-Alcoholic Fatty Liver Disease Analyst Review
20. Appendix
21. Report Methodology

Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/non-alcoholic-fatty-liver-disease-nafld-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.